PPSS-GROUP
PPSS Group's next generation of high-performance body armour is taking personal protection to a completely new-found level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005491/en/
Thoroughly field tested, the body armour will be made available from Monday 06 January 2020. A demonstration of the body armour is available to view here .
Made from Auxilam™, a unique carbon fibre composite material, this latest body armour will protect the wearer from even the most vicious and brutal types of edged weapon and shanks imaginable.
Utilising a combination of the incredible strength of carbon fibre, the auxetic properties of Auxilam™ technology and some additional ‘top secret’ assets derived from the specially developed composite structure, this next generation of body armour offers a truly outstanding balance of weight, protection, performance and durability.
Comparing it with PPSS Group’s highly acclaimed polycarbonate-based stab resistant vests, the company is claiming a reduction of 19% in thickness (utilising a 3.9mm carbon fibre composite) and a 6.6% lower aerial density and reduced weight for its latest development.
Yet, it will be certified to KR2/SP2 according to the UK Home Office Body Armour Standard, as well as NIJ Level 2 (Stab & Spike) and VPAM K2/D2 meaning it will offer a truly significant higher level of knife, spike and needle protection.
Government agencies and security companies will be able to chose from an array of different styles, ranging from covert, overt to hi viz overt options.
Robert Kaiser, CEO of PPSS Group states: “Law Enforcement, Border Force, Immigration, Customs and Prison Officers are being attacked by criminals carrying and using knives, machetes, shanks, blunt objects and hypodermic needles every day.”
“Our key objective is to protect those men and women even more effectively. Using the very latest in technology and following extensive research and development, our latest body armour is now offering previously absolutely unthinkable levels of protection.”
“It also offers exceptional, VPAM certified protection from blunt objects, effectively reducing the risks of blunt force trauma injuries e.g. internal bleeding.”
The UK headquartered firm has been supplying countless of homeland security agencies in countries around the world with their widely respected polycarbonate-based stab resistant vests over the past ten years.
Please contact PPSS Group directly in case you have any questions in regards to this press release.
About PPSS Group:
PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. PPSS Group’s social media presence: Facebook , LinkedIn , Twitter , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005491/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom